Phase 3 Vitiligo Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Children aged 6 to under 12 years old at the time of signing the consent form
• Children diagnosed with a specific type of vitiligo called "nonsegmental vitiligo," affecting at least 0.5% of the face area and at least 3% of body areas other than the face
• The total vitiligo area on the body does not cover more than 10% of the body
• Some of the vitiligo patches on the face still have hair that has kept its natural color (pigmented hair)
• The participant must agree to stop using all vitiligo treatments from the start of the study through the final follow-up visit
• Participants who are sexually active (and past puberty) must agree to take steps to avoid pregnancy or fathering a child during the study, as outlined by the study team

Who may not be able to join:

• Children diagnosed with other types of vitiligo, such as segmental vitiligo
• Children with other skin conditions that cause loss of skin color (such as piebaldism, leprosy, or fungal skin infections, among others)
• Children with any other skin condition that the study doctor feels could interfere with applying the cream or completing the study assessments
• Children who have previously used or are currently using treatments designed to permanently remove skin pigment (such as monobenzone)
• Children with certain serious illnesses, or physical or mental health conditions that the study doctor believes could make full participation unsafe or interfere with study results
• Children who have used certain treatments too recently before the study starts (specific waiting periods apply — confirm with trial site)
• Children who have previously tried a type of medication called a JAK inhibitor (for vitiligo or another inflammatory condition) without success
• Children with certain abnormal blood or lab test results found at the screening visit (confirm with trial site)
• Children whose weight-for-age falls below the 5th percentile or at or above the 85th percentile on the CDC child BMI chart
• Participants who are pregnant, breastfeeding, or planning to become pregnant during the study
• Children who, in the study doctor's opinion, are unlikely to follow the cream application schedule or attend required study visits
• Children living in the same household as someone already taking part in another Incyte-sponsored ruxolitinib cream study
• Children who are employees of the study sponsor or investigator, or who are dependents of those employees
• Children with a known allergy or reaction to any ingredient in the study cream
• In France and EU countries, certain additional legal protections may prevent some children from being eligible (confirm with trial site)

Other eligibility rules set by the study protocol may also apply.

Important: Always verify eligibility with the trial site directly before applying.